<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE- trimethoprim sulfate and polymyxin b sulfate solution </strong><br>Akorn, Inc.<br></p></div>
<h1>Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is a sterile antimicrobial solution for topical ophthalmic use. Trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine sulfate (2:1), occurs as a white, odorless, crystalline powder with a molecular weight of 678.72. The structural formula is as follows:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=507c7308-6526-40d7-b8aa-3ca7b5d8cc17&amp;name=tri0a-0000-01.jpg">
</div>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula is as follows:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=507c7308-6526-40d7-b8aa-3ca7b5d8cc17&amp;name=tri0a-0000-02.jpg">
</div>
<p><span class="Bold">Each mL contains:</span></p>
<p><span class="Bold">Actives:</span> Trimethoprim Sulfate equivalent to Trimethoprim 1 mg (0.1%) and Polymyxin B Sulfate 10,000 units. Preservative: Benzalkonium Chloride 0.04 mg (0.004%). <span class="Bold">Inactives:</span> Sodium Chloride, Sulfuric Acid and Sodium Hydroxide may be added to adjust pH (3.0 to 5.5), and Purified Water USP.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Trimethoprim is a synthetic antibacterial drug active against a wide variety of aerobic gram-positive and gram-negative ophthalmic pathogens. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the enzyme dihydrofolate reductase. This binding is very much stronger for the bacterial enzyme than for the corresponding mammalian enzyme. For that reason, trimethoprim selectively interferes with bacterial biosynthesis of nucleic acids and proteins.
</p>
<p>Polymyxin B, a cyclic lipopeptide antibiotic, is rapidly bactericidal for a variety of gram-negative organisms, especially <span class="Italics">Pseudomonas aeruginosa</span>. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.
</p>
<p>When used topically, trimethoprim and polymyxin B absorption through intact skin and mucous membranes is insignificant.
</p>
<p>Blood samples were obtained from 11 human volunteers at 20 minutes, 1 hour and 3 hours following instillation in the eye of 2 drops of ophthalmic solution containing 1 mg trimethoprim and 10,000 units polymyxin B per mL. Peak serum concentrations were approximately 0.03 mcg/mL trimethoprim and 1 unit/mL polymyxin B.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:
</span><span class="Italics">In vitro</span> studies have demonstrated that the anti-infective components of Trimethoprim and Polymyxin B Sulfate Ophthalmic Solution are active against the following bacterial pathogens that are capable of causing external <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Trimethoprim:
</span><span class="Italics">Staphylococcus aureus and Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus aegyptius, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis</span> (indole-negative), <span class="Italics">Proteus vulgaris</span> (indole-positive), <span class="Italics">Enterobacter aerogenes, and Serratia marcescens.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Polymyxin B:
</span><span class="Italics">Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes and Haemophilus influenzae.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, including acute bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, and <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>, caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms:
</p>
<p><span class="Italics">Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> and Pseudomonas aeruginosa.</span>*
</p>
<p>*Efficacy for this organism in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First"><span class="Bold">NOT FOR INJECTION INTO THE EYE.</span> If a sensitivity reaction to Trimethoprim and Polymyxin B Sulfate Ophthalmic Solution occurs, discontinue use. Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is not indicated for the prophylaxis or treatment of ophthalmic neonatorum.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s10"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s11"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> As with other antimicrobial preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate therapy should be initiated.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s12"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Avoid contaminating the applicator tip with material from the eye, fingers, or other source. This precaution is necessary if the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the drops is to be maintained.
</p>
<p>If <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, irritation, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists or increases, discontinue use immediately and contact your physician.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s13"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-7.3.1"></a><p></p>
<p class="First"><span class="Bold Italics">Carcinogenesis:</span> Long-term studies in animals to evaluate carcinogenic potential have not been conducted with polymyxin B sulfate or trimethoprim.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.3.2"></a><p></p>
<p class="First"><span class="Bold Italics">Mutagenesis:</span> Trimethoprim was demonstrated to be non-mutagenic in the Ames assay. In studies at two laboratories no chromosomal damage was detected in cultured Chinese hamster ovary cells at concentrations approximately 500 times human plasma levels after oral administration; at concentrations approximately 1000 times human plasma levels after oral administration in these same cells a low level of chromosomal damage was induced at one of the laboratories. Studies to evaluate mutagenic potential have not been conducted with polymyxin B sulfate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-7.3.3"></a><p></p>
<p class="First"><span class="Bold Italics">Impairment of Fertility:</span> Polymyxin B sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.
</p>
<p>No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s17"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:
</span><span class="Bold Italics">Teratogenic Effects</span></p>
<p>Pregnancy Category C. Animal reproduction studies have not been conducted with polymyxin B sulfate. It is not known whether polymyxin B sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
</p>
<p>Trimethoprim has been shown to be teratogenic in the rat when given in oral doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with oral doses 6 times the human therapeutic dose.
</p>
<p>While there are no large well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell, in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or oral trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received oral trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter. Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<div class="Section" data-sectionCode="34078-6">
<a name="s18"></a><a name="section-7.4.1"></a><p></p>
<p class="First"><span class="Bold Italics">Nonteratogenic Effects:</span> The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s19"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold Italics">Nursing mothers:</span> It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s20"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Use:</span> Safety and effectiveness in pediatric patients below the age of 2 months have not been established (see <a href="#s9">WARNINGS</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s21"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">The most frequent adverse reaction to Trimethoprim Sulfate and Polymxin B Sulfate Ophthalmic Solution is local irritation consisting of increased <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, and/or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> consisting of lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, increased <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, tearing, and/or circumocular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> has been reported in patients taking oral trimethoprim.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s22"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Adults:</span> In mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Clinical studies have shown Trimethoprim and Polymyxin B Sulfate Ophthalmic Solution to be safe and effective for use in pediatric patients over two months of age. The dosage regimen is the same as for adults.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s25"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is supplied as a sterile solution in plastic dropper bottles in the following size: 10 mL in a 10 mL bottle NDC 17478-703-11
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s26"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">STORAGE:</span> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
</p>
<p><span class="Bold">WARNING – KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.</span></p>
<p><span class="Bold">Akorn</span></p>
<p>Manufactured by: Akorn, Inc.<br>Lake Forest, IL 60045
</p>
<p>ATP00N<br>Rev. 10/08
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s27"></a><a name="section-11"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 17478-703-11
</p>
<p>Trimethoprim Sulfate
</p>
<p>and Polymyxin B
</p>
<p>Sulfate Ophthalmic
</p>
<p>Solution
</p>
<p>10 mL
</p>
<p>For the eye
</p>
<p>Sterile
</p>
<p>Rx only                         [Akorn Logo]
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=507c7308-6526-40d7-b8aa-3ca7b5d8cc17&amp;name=tri0a-0000-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s28"></a><a name="section-12"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-703-11
</p>
<p>Trimethoprim
</p>
<p>Sulfate and
</p>
<p>Polymyxin B
</p>
<p>Sulfate
</p>
<p>Ophthalmic
</p>
<p>Solution
</p>
<p>For the eye
</p>
<p>10 mL
</p>
<p>Sterile
</p>
<p>Rx only                    [Akorn Logo]
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=507c7308-6526-40d7-b8aa-3ca7b5d8cc17&amp;name=tri0a-0000-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE 		
					</strong><br><span class="contentTableReg">trimethoprim sulfate and polymyxin b sulfate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-703</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Trimethoprim sulfate</strong> (Trimethoprim) </td>
<td class="formItem">Trimethoprim sulfate</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Polymyxin B sulfate</strong> (Polymyxin B) </td>
<td class="formItem">Polymyxin B sulfate</td>
<td class="formItem">10000 [USP'U]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sulfuric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-703-11</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065006</td>
<td class="formItem">12/17/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc.</td>
<td class="formItem"></td>
<td class="formItem">155135783</td>
<td class="formItem">MANUFACTURE, REPACK, ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ad0796b0-1f91-46a5-a18d-4b315ee95fe0</div>
<div>Set id: 507c7308-6526-40d7-b8aa-3ca7b5d8cc17</div>
<div>Version: 2</div>
<div>Effective Time: 20110909</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
